Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

PURPOSE: KEYNOTE-224 cohort 1 demonstrated that pembrolizumab was efficacious and tolerable in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib. We report results from KEYNOTE-224 (NCT02702414) cohort 2, which enrolled patients with advanced HCC and no prior sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Verset, Gontran, Borbath, Ivan, Karwal, Mark, Verslype, Chris, Van Vlierberghe, Hans, Kardosh, Adel, Zagonel, Vittorina, Stal, Per, Sarker, Debashis, Palmer, Daniel H., Vogel, Arndt, Edeline, Julien, Cattan, Stephane, Kudo, Masatoshi, Cheng, Ann-Lii, Ogasawara, Sadahisa, Daniele, Bruno, Chan, Stephen L., Knox, Jennifer J., Qin, Shukui, Siegel, Abby B., Chisamore, Michael, Hatogai, Ken, Wang, Anran, Finn, Richard S., Zhu, Andrew X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784157/
https://www.ncbi.nlm.nih.gov/pubmed/35421228
http://dx.doi.org/10.1158/1078-0432.CCR-21-3807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784157/
https://www.ncbi.nlm.nih.gov/pubmed/35421228
http://dx.doi.org/10.1158/1078-0432.CCR-21-3807

Ejemplares similares